Mytos (YC Summer 2018)

TL;DR: Mytos is a Y Combinator Summer 2018 startup Robotic human cell manufacturing, currently active with a team of 26.

Robotic human cell manufacturing

YC ID
1967
YC Batch
Summer 2018
Status
Active
Team size
26
Industry
Healthcare, Industrial Bio
Tags
Hardware, IoT, Biotech
YC profile
https://www.ycombinator.com/companies/cytera-cellworks

Last verified:

Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks. Last year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global capacity to produce these cells, and treat millions of patients. But today these Regenerative Medicines are produced by hand, meaning they’re too expensive and don’t scale. Mytos has fully automated production of these cells, making it scalable. We have our first manufacturing deal - neurons for treating Parkinson’s - and we’re in conversations with majority of the other top players.

Built by LemStudio

Building or buying SaaS? Try our founder tools →

Frequently asked questions

Is Mytos a YC (Y Combinator) company?

Yes. Mytos was funded by Y Combinator in the Summer 2018 batch. Robotic human cell manufacturing

What does Mytos do?

Mytos builds robots for manufacturing human cells. Operators input stem cells, and our platform turns them into specific cells such as neurons and heart cells over multiple weeks. Last year, patients were cured of Parkinson’s, vision loss, and Type 1 diabetes using stem-cell derived cells. We need 1000x the global cap…

What YC batch was Mytos in?

Mytos was part of Y Combinator's Summer 2018 batch.

How big is Mytos?

Mytos has a team of 26 people according to Y Combinator's directory.

Is Mytos still active?

Mytos is currently listed as Active with a team of 26 in Y Combinator's directory.

More YC Summer 2018 companies

More Healthcare YC startups

Explore related YC hubs

Loading interactive view…